Purified human anti-Tn and anti-T antibodies specifically recognize carcinoma tissues.

Described in several epithelial cancer cells, Tn- (GalNAcα1-O-Ser/Thr) and T- (Galß3GalNAcα1-O-Ser/Thr) antigens are examples of tumor-associated antigens. Increased expression of Tn- and T-antigens is associated with tumor invasion and metastasis, and patients with high concentration of anti-Tn and anti-T antibodies have a more benign evolution of pathology. Asialofetuin (ASF) and ovine submaxillary mucin (OSM) are two glycoproteins that expose T- and Tn-antigen, respectively. In this work, using ASF or OSM we affinity-purified anti-T and anti-Tn antibodies from normal human plasma and tested their ability to specifically recognize tumor human tissues. Whereas purified anti-T antibodies (purity degree increase of 127-fold, and 22% recovery) were mainly IgG, for purified anti-Tn antibodies (purity degree enhancement of 125-fold, and 26% yield) the IgM fraction was predominant over the IgG one. IgG2 subclass was significantly enriched in both purified antibody samples. Purified antibodies did not bind normal human tissue (0/42), although recognized malignant tissues from different origin such as colon carcinoma (11/77 by anti-Tn; 7/79 by anti-T), breast carcinoma (10/23 by anti-Tn; 7/23 by anti-T), and kidney carcinoma (45/51 by anti-Tn; 42/51 by anti-T). Our results suggest that purified human anti-Tn and anti-T antibodies have a potential as anti-tumor therapeutic agents; restoring their levels in human sera could positively affect the evolution of patients with epithelial tumor pathologies.

Solid-phase assays of receptor-binding specificity.

Influenza virus attachment to sialic acid-containing molecules on the cell surface initiates the infection. The spectrum of functional receptors on target cells and decoy receptors on cells and epithelial mucus varies substantially between animal species leading to variations in the receptor-binding specificity of viruses circulating in these species. Analysis of the receptor specificity of different animal and human influenza viruses can give insight into factors and mechanisms that determine viral host range, tissue and cell tropism, replication efficiency, and pathogenesis. Knowledge of viral receptor specificity may also be useful for the development of more efficient influenza vaccines and anti-influenza drugs.A majority of known receptor specificity assays measure influenza virus binding to sialic acid-containing natural and synthetic compounds (receptor analogues). Here, we describe protocols of two solid-phase enzyme-linked receptor-binding assays which are technically similar to standard ELISA. Each assay determines binding of the virus immobilized in the wells of 96-well plate to receptor analogues in solution. In the direct binding assay, the virus binds to either synthetic biotinylated sialylglycopolymers or to peroxidase-labeled sialylglycoprotein fetuin (Fet-HRP); the apparent association constants of the virus-receptor complexes are calculated from the Scatchard plots of the binding data. In the fetuin-binding inhibition assay, the virus is incubated with a mixture of unlabeled receptor analogue and standard preparation of Fet-HRP; the association constant for analogue is calculated based on the level of its competition with Fet-HRP.